Block 61 Drilling Fluids Optimization Journey

2021 ◽  
Author(s):  
Majda Jan Mohammad ◽  
Muneer Al Noumani ◽  
Iain Cameron ◽  
Younis Al Masoudi
Keyword(s):  
Cost Saving ◽  
Continuous Improvement ◽  
Cost Savings ◽  
Cost Benefit ◽  
Drilling Fluids ◽  
Well Performance ◽  
Drilling Performance ◽  
Delivery Times ◽  
Wellbore Strengthening ◽  
The Cost

Abstract BP operates Khazzan & Ghazeer fields in the Sultanate of Oman with the aim to deliver safe, reliable and efficient wells. Efficiencies within drilling fluids design form part of a greater continuous improvement cycle to well delivery cost. With fluids spend contributing to a significant portion of the executed well cost (typically 15 % in Oman), fluids design changes hold the potential to yield positive cost savings (where well performance is maintained). This paper presents the areas of fluids design which were explored to reduce fluids spend as part of the continuous improvement cycle. Combined, the changes to fluids design evolved to reduce the fluids cost of Barik vertical wells to 6% of total well cost. All avenues of fluids design and the costs associated with the fluids operation in Oman were viewed as being in scope for change to maintain overbalance hydrostatic pressure on fluids spend. The methodology employed to reduce fluids spend can be described in four steps as per continuous improvement roadmaps; identify the cost saving project, the key enablers which allow the cost saving to be realized, risk/reward analysis where low risk/high reward projects were accelerated as priority and placed to the front of the queue for field trial and where a trial outcome is positive, the change is introduced permanently to the operation. This process worked well in continuously pushing fluid performance and reducing the fluids spend in Oman. The scope of change to fluids design was wide, with each ‘value adding project’ providing its own cumulative cost benefit. The projects which contributed to significantly reducing the overall fluids spend in Oman focused on personnel, fluid type selection, fluids formulation optimization, wellbore strengthening, fluid consumption and recycling, drilling fluids practice and brine selection. Reductions in fluids spend were accompanied with an improved well performance. Well delivery times being continuously observed to improve throughout the campaign (63 days vs 42 days). Whilst the fluids design is not directly responsible for this outcome, it does highlight that the changes made to fluids design positively influenced the improved well delivery performance. The drilling fluids optimization initiatives resulted in significant time and cost saving thus reduction in overall Barik vertical well drilling cost. Drilling fluids cost is reduced by over 55% without impact on safety and drilling performance.

Drilling Automation – Benefits of the New Drilling Model

2021 ◽  
Author(s):  
Jorge Heredia ◽  
Jan Egil Tengesdal ◽  
Rune Hobberstad ◽  
Julien Marck ◽  
Harald Kleivenes ◽  
...  
Keyword(s):  
Conventional Method ◽  
Three Dimensional ◽  
Cost Savings ◽  
Work Force ◽  
Directional Drilling ◽  
Well Performance ◽  
Human Errors ◽  
Drilling Performance ◽  
Friction Factors ◽  
Remote Operations

Abstract A pilot program for automated directional drilling was implemented as a part of the roll out plan in Norway to drill three dimensional wells in an automated mode, where steering commands were carried out automatically by the automation platform. The rollout plan also targeted the use of remote operations to allow personnel to be relocated from the rig location into remote drilling centers. The goal of the program was to optimize the directional drilling performance by assessing the benefits of automation using the latest rotary steerable system technologies and machine learning smart algorithms to predict and manipulated the BHA performance, as well as the ability to predict the best drilling parameters for hole cleaning. The automation was implemented on three different rigs and the data was compared with the drilling performance from the last two years, with three dimensional wells drilled in the conventional method. The main benefits between drilling wells in the conventional method versus drilling wells with the new drilling automation model include the following. Reduce the overall cost per meter –  Improve the rate of penetration –  Improve running casings Consistence process adherence –  Reduce human errors –  Reduce POB without sacrificing lost of technical experience Optimize workforce resources –  Allows continuity of service (COVID-19 restrictions) Drilling automation can drill smoother wells by reducing the friction factors and tortuosity. This is translated in direct cost savings per meter and reduction in the overall well delivery time, with the advantage of performing the execution and monitoring of the well performance remotely. This new drilling model open the door of new opportunities, especially for the challenges where the work force resources, and drilling performance is a priority for the operations.

scholarly journals Cost–effectiveness and cost-benefit analysis of oliceridine in the treatment of acute pain

2021 ◽  
Author(s):  
Kit N Simpson ◽  
Michael J Fossler ◽  
Linda Wase ◽  
Mark A Demitrack
Keyword(s):  
Cost Benefit Analysis ◽  
Cost Savings ◽  
Cost Benefit ◽  
Cost Effective ◽  
Adverse Outcomes ◽  
Protein Signaling ◽  
Opioid Receptor Agonist ◽  
Cost Effective Alternative ◽  
Μ Opioid Receptor ◽  
The Cost

Aim: Oliceridine, a new class of μ-opioid receptor agonist, is selective for G-protein signaling (analgesia) with limited recruitment of β-arrestin (associated with adverse outcomes) and may provide a cost-effective alternative versus conventional opioid morphine for postoperative pain. Patients & methods: Using a decision tree with a 24-h time horizon, we calculated costs for medication and management of three most common adverse events (AEs; oxygen saturation <90%, vomiting and somnolence) following postoperative oliceridine or morphine use. Results: Using oliceridine, the cost for managing AEs was US$528,424 versus $852,429 for morphine, with a net cost savings of $324,005. Conclusion: Oliceridine has a favorable overall impact on the total cost of postoperative care compared with the use of the conventional opioid morphine.

scholarly journals A Comparison of Three Ridesharing Cost Savings Allocation Schemes Based on the Number of Acceptable Shared Rides

Energies ◽  
2021 ◽  
Vol 14 (21) ◽  
pp. 6931
Author(s):  
Fu-Shiung Hsieh
Keyword(s):  
Air Pollution ◽  
Cost Saving ◽  
Comparative Study ◽  
Cost Savings ◽  
Research Community ◽  
Transportation Mode ◽  
Strong Incentive ◽  
Shared Mobility ◽  
Develop Theory ◽  
The Cost

Shared mobility based on cars refers to a transportation mode in which travelers/drivers share vehicles to reduce the cost of the journey, emissions, air pollution and parking demands. Cost savings provide a strong incentive for the shared mobility mode. As cost savings are due to cooperation of the stakeholders in shared mobility systems, they should be properly divided and allocated to relevant participants. Improper allocation of cost savings will lead to dissatisfaction of drivers/passengers and hinder acceptance of the shared mobility mode. In practice, several schemes based on proportional methods to allocate cost savings have been proposed in shared mobility systems. However, there is neither a guideline for selecting these proportional methods nor a comparative study on effectiveness of these proportional methods. Although shared mobility has attracted much attention in the research community, there is still a lack of study of the influence of cost saving allocation schemes on performance of shared mobility systems. Motivated by deficiencies of existing studies, this paper aims to compare three proportional cost savings allocation schemes by analyzing their performance in terms of the numbers of acceptable rides under different schemes. We focus on ridesharing based on cars in this study. The main contribution is to develop theory based on our analysis to characterize the performance under different schemes to provide a guideline for selecting these proportional methods. The theory developed is verified by conducting experiments based on real geographical data.

Economic impact and cost savings of teledermatology units compared to conventional monitoring at hospitals in southern Spain

2020 ◽  
pp. 1357633X2094204
Author(s):  
Antonio Lopez-Villegas ◽  
Rafael Jesus Bautista-Mesa ◽  
Miguel Angel Baena-Lopez ◽  
Maria Luisa Alvarez-Moreno ◽  
Jesus E Montoro-Robles ◽  
...  
Keyword(s):  
Cost Saving ◽  
Health Care Systems ◽  
Cost Savings ◽  
Public Health Care ◽  
Retrospective Assessment ◽  
Care Systems ◽  
Cost Of Time ◽  
One Year ◽  
The Cost

Introduction Asynchronous teledermatology (TD) has undergone exponential growth in the past decade, allowing better diagnosis. Moreover, it saves both cost and time and reduces the number of visits involving travel and opportunity cost of time spent on visits to the hospital. The present study performed a cost-saving analysis of TD units and assessed whether they offered a cheaper alternative to conventional monitoring (CM) in hospitals from the perspective of public health-care systems (PHS) and patients. Methods This study was a retrospective assessment of 7030 patients. A cost-saving analysis comparing TD units to CM for patients at the Hospital de Poniente was performed over a period of one year. The TD network covered the Hospital de Poniente reference area (Spain) linked to 37 primary care (PC) centres that belonged to the Poniente Health District of Almeria. Results We observed a significant cost saving for TD units compared to participants in the conventional follow-up group. From the perspective of a PHS, there was a cost saving of 31.68% in the TD group (€18.59 TD vs. €27.20 CM) during the follow-up period. The number of CM visits to the hospital reduced by 38.14%. From the patients’ perspective, the costs were lower, and the cost saving was 73.53% (€5.45 TD vs. €20.58 CM). Discussion The cost-saving analysis showed that the TD units appeared to be significantly cheaper compared to CM.

Cost-benefit analysis of AR-V7 testing in patients (Pts) with metastatic castration resistant prostate cancer (mCRPC) eligible for abiraterone (Abi) or enzalutamide (Enza).

2016 ◽  
Vol 34 (2_suppl) ◽  
pp. 283-283
Author(s):  
Mark Christopher Markowski ◽  
Kevin D. Frick ◽  
James R. Eshleman ◽  
Jun Luo ◽  
Emmanuel S. Antonarakis
Keyword(s):  
Cost Benefit Analysis ◽  
Cost Savings ◽  
Cost Benefit ◽  
Benefit Analysis ◽  
Castration Resistant Prostate Cancer ◽  
The Us ◽  
Effective Option ◽  
Current Price ◽  
Societal Challenge ◽  
The Cost

283 Background: The rising cost of oncology care in the US is an ongoing societal challenge, and identifying biomarkers that inform clinical decisions and reduce the use of ineffective therapies remains elusive. A splice variant of the androgen receptor, AR-V7, was found to confer resistance to Abi and Enza in men with mCRPC, but did not negatively affect responses to taxanes, suggesting that early use of chemotherapy may be a more effective option for AR-V7(+) pts. With the recent development of a CLIA-certified clinical assay for AR-V7 at Johns Hopkins, we hypothesized that AR-V7 testing in mCRPC pts may result in cost savings by avoiding futile treatment with Abi/Enza in men with AR-V7(+) disease. Methods: We calculated the cost savings of performing AR-V7 testing in mCRPC pts prior to starting Abi/Enza (and avoiding these drugs in AR-V7(+) men) versus treating all mCRPC pts with Abi/Enza (without use of the biomarker). We have set the cost of the AR-V7 assay at $1000. The cost of 3 months of Abi/Enza (the minimum time it would take to determine resistance, clinically) was approximated at $20,000. We estimated that 30,000 mCRPC pts per year are eligible for Abi/Enza in the US. Results: In our prior studies, about 30% of mCRPC pts previously treated with Abi/Enza had detectable AR-V7 in CTCs. Assuming an AR-V7 prevalence of 30%, about 9,000 AR-V7(+) mCRPC pts per year would receive ineffective treatment with Abi/Enza, at an estimated cost of $180 Million. The upfront cost of testing all mCRPC pts who are Abi/Enza-eligible for AR-V7 is $30 Million, resulting in a net cost savings of $150 Million. When performing a continuous cost-benefit analysis after assuming other prevalences of AR-V7 (ranging from 4% to 50%) and a range of costs for Abi/Enza ($2000 to $24,000 per 3 months), we determined that AR-V7 testing would result in a cost savings as long as the prevalence of AR-V7 is > 5% (if the cost of 3 months of Abi/Enza remains at $20,000). Conclusions: AR-V7 testing in mCRPC pts (at $1000/test) is cost-beneficial when considering the current price of Abi/Enza, and may reduce the ineffective use of Abi/Enza leading to a net cost savings to the healthcare system.

scholarly journals Modelling the dynamic effects of elective hospital admissions on emergency levels in England

2019 ◽  
Vol 59 (4) ◽  
pp. 1933-1957
Author(s):  
Sergi Jimenez-Martin ◽  
Catia Nicodemo ◽  
Stuart Redding
Keyword(s):  
Cost Saving ◽  
Fixed Effects ◽  
Hospital Admissions ◽  
Primary Care Trust ◽  
Cost Savings ◽  
Unintended Consequences ◽  
Policy Makers ◽  
Elective Treatment ◽  
Life Threatening ◽  
The Cost

Abstract In England as elsewhere, policy makers are trying to reduce the pressure on costs due to rising hospital admissions by encouraging GPs to refer fewer patients to hospital specialists. This could have an impact on elective treatment levels, particularly procedures for conditions which are not life-threatening and can be delayed or perhaps withheld entirely. This study attempts to determine whether cost savings in one area of publicly funded health care may lead to the increases in cost in another and therefore have unintended consequences by offsetting the cost-saving benefits anticipated by policy makers. Using administrative data from Hospital Episode Statistics in England, we estimate dynamic fixed effects panel data models for emergency admissions at Primary Care Trust and Hospital Trust levels for the years 2004–2013, controlling for a group of area-specific characteristics and other secondary care variables. We find a negative link between current levels of elective care and future levels of emergency treatment. This observation comes from a time of growing admissions, and there is no guarantee that the link between emergency and elective activity will persist if policy is effective in reducing levels of elective treatment, but our results suggest that the cost-saving benefits to the NHS from reducing elective treatment are reduced by between 5.6 and 15.5% in aggregate as a consequence of increased emergency activity.

scholarly journals Economic evaluation of passive monitoring technology for seniors

2019 ◽  
Vol 32 (7) ◽  
pp. 1375-1382
Author(s):  
John E. Schneider ◽  
Jacie Cooper ◽  
Cara Scheibling ◽  
Anjani Parikh
Keyword(s):  
Health Care ◽  
Conceptual Model ◽  
Independent Living ◽  
Care Pathway ◽  
Cost Savings ◽  
Cost Benefit ◽  
Standard Of Care ◽  
Passive Monitoring ◽  
Monitoring Technology ◽  
The Cost

Abstract Background Advances such as passive monitoring technology (PMT), which provides holistic supervision of chronically ill and elderly patients, enable and support improved monitoring and observation, thus empowering the growing population of older adults to live more independently while lowering health care expenses. Aims This study develops a conceptual model to estimate the potential savings associated with PMT. Methods We first develop a conceptual model to identify the main cost variables associated with independent living, focusing on three pathways: (1) PMT, (2) independent living supported by the current standard of care, and (3) facility-based care. We examined the impact on three outcomes [i.e., health care costs, institutional costs, and health-related quality of life (HRQoL)] along each of the three care pathways (i.e., PMT, independent living supported by the standard of care, and facility-based care) and developed a cost-benefit model to calculate the net costs and benefits associated with each care pathway. Results The cost–benefit model showed savings between approximately $425 per-member per-month (PMPM) for those using PMT compared to those on the standard of care pathway. Sensitivity analysis demonstrated that a 5% increase in nursing home utilization generates cost savings of more than 30% PMPM. Discussion The total projected cost savings for individuals on the PMT arm are projected to be more than $425 PMPM, with annual savings of $5069 per-person per-year, and over $5.1 million for a target population of 1000 individuals. Conclusions The cost calculations in our cost–benefit simulation model clearly demonstrate the value of PMT and show the potential value to payers and integrated delivery systems in offering PMT to individuals who are likely to benefit the most from the services.

Cost Savings and Service Strategies in the British National Bibliographic Service

1989 ◽  
Vol 1 (2) ◽  
pp. 17-26
Author(s):  
Peter Lewis
Keyword(s):  
Action Plan ◽  
Cost Savings ◽  
Cost Benefit ◽  
International Standards ◽  
British Library ◽  
Library Community ◽  
Data Content ◽  
The Cost ◽  
Service Strategies

The British Library launched in 1986 a Catalogue Action Plan to deal with the long-term prospect of declining financial and manpower resources, the absence of growth in the market for its services, an unacceptably large backlog of uncatalogued materials, and a steadily increasing annual output of British publications to be catalogued. The initial phase of the Plan was designed to contain staff costs by reduction and simplification in data content in BNBMARC and other British Library records, predicating their future use primarily in an online (OPAC) environment. It has had significant success for the British Library's aims in the first full year of implementation, but it has raised questions of the cost-benefit in centralized cataloguing services for the library community, in respect both of the costs and sizing of OPAC systems in local libraries and of the necessity of sustaining indefinitely the high cost of adherence to international standards established before OPACs, the CD-ROMs and OSI had changed the technology.

Costo-beneficio del trattamento con i farmaci antivirali ad azione diretta nei consumatori di sostanze con epatite C: una valutazione del percorso di point of care

MISSION ◽  
2021 ◽  
pp. 8-17
Author(s):  
Felice A. Nava ◽  
Lucia Trevisi ◽  
Alfio Lucchini
Keyword(s):  
Public Health ◽  
Cost Saving ◽  
Drug Users ◽  
Cost Benefit Analysis ◽  
Point Of Care ◽  
Cost Benefit ◽  
Health Concern ◽  
Hcv Treatment ◽  
The Public ◽  
The Cost

Background Hepatitis C is a disease correlated with severe systemic consequences having elevated social and health costs. The HCV elimination is a public health concern that may be solved reaching DAAs treatment for drug users. The principal aim of this work is to evaluate the cost-benefit of a point of care for HCV treatment of drug users inside Drug abuse services (Ser.D.). Methods The study consists in a cost-benefit analysis able to evaluate the "return of health" induced by a point of care for a HCV treatment. Results The work shows that the point of care is cost-benefit in comparison with the "traditional" treatment being cost saving for the public health system. The data suggest that the cost of the point of care is corresponding to euros 593,40 while the cost of not treatment of euros 8.679,60 (due to the direct and indirect costs of the disease). Conclusions The study demonstrate the point of care is an effective model of care able to reduce the barriers of treatment and to induce a "health return" in term of cost saving for the public health systems. Indeed, the work shows how the point of care may make the elimination HCV plans sustainable for the public health agencies.

scholarly journals Cost Comparisons between Home- and Clinic-Based Testing for Sexually Transmitted Diseases in High-Risk Young Women

2007 ◽  
Vol 2007 ◽  
pp. 1-5 ◽  
Author(s):  
Kenneth J. Smith ◽  
Robert L. Cook ◽  
Roberta B. Ness
Keyword(s):  
Cost Effectiveness ◽  
Cost Saving ◽  
Controlled Trial ◽  
Cost Savings ◽  
Indirect Costs ◽  
Sexually Transmitted ◽  
Home Based ◽  
Home Testing ◽  
Testing Cost ◽  
The Cost

Home testing for chlamydia and gonorrhea increases screening rates, but the cost consequences of this intervention are unclear. We examined the cost differences between home-based and clinic-based testing and the cost-effectiveness of home testing based on the DAISY study, a randomized controlled trial. Direct and indirect costs were estimated for home and clinic testing, and cost-effectiveness was calculated as cost per additional test performed. In the clinic testing group, direct costs were $49/test and indirect costs (the costs of seeking or receiving care) were $62/test. Home testing cost was $25/test. We found that home testing was cost saving when all testing for all patients was considered. However cost savings were not seen when only asymptomatic tests or when patient subgroups were considered. A home testing program could be cost saving, depending on whether changes in clinic testing frequency occur when home testing is available.

Sign in / Sign up

Export Citation Format

Share Document